Latest Filings

Issuer Activity

Overview :: McKesson Corporation (N:MCK) [?]
Business Focus: Drug Retailers Share on StockTwits
Recent Price for MCK
USD 192.000 -1.450 (-0.750%)
NYSE Delayed 15 minutes
Aug 22 Close
1-Day High 52-Week High P/E 1-Day Volume Mkt Cap ($Mil)
193.940 196.440 36.13 963,358 44,544.00
1-Day Low 52-Week Low Yield Avg. Volume  
191.630 120.170 0.5% NYSE  
Log in or sign up for a free account to add this stock to your watch list. During beta also get free PDF company reports for US stocks.

Latest 10 SEC filings (by transaction date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:21pm ET August 22nd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 11/14 Aug 8/14 Jacobs M Christine Direct Ownership Common Stock S - Open market or private sale -2,619 $189.88
Aug 6/14 Aug 5/14 Tyler Brian Scott Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 1,467  
Aug 6/14 Aug 5/14 Schechter Lori A. Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 14,419  
Aug 6/14 Aug 5/14 Knowles Marie L/Ca Direct Ownership Common Stock S - Open market or private sale -785 $192.10
Aug 8/14 Jul 30/14 Mueller Edward A Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 131  
Jul 31/14 Jul 30/14 Budd Wayne A Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Knowles Marie L/Ca Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Mueller Edward A Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Lawrence David M Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Jacobs M Christine Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Latest 10 SEC filings (by filing date) for MCK within the last 6 months [?]
Amended Filing      Footnote and/or Remark
As of 11:21pm ET August 22nd, 2014
Filing
Date
Transaction
Date
Insider Name Ownership
Type
Securities Nature of transaction # or value acquired or disposed of Price
Aug 11/14 Aug 8/14 Jacobs M Christine Direct Ownership Common Stock S - Open market or private sale -2,619 $189.88
Aug 8/14 Jul 30/14 Mueller Edward A Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 131  
Aug 6/14 Aug 5/14 Tyler Brian Scott Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 1,467  
Aug 6/14 Aug 5/14 Schechter Lori A. Direct Ownership Employee Stock Option (Right-to-buy) A - Grant, award or other under Rule 16b-3(d) 14,419  
Aug 6/14 Aug 5/14 Knowles Marie L/Ca Direct Ownership Common Stock S - Open market or private sale -785 $192.10
Jul 31/14 Jul 30/14 Budd Wayne A Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Knowles Marie L/Ca Direct Ownership Common Stock A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Mueller Edward A Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Lawrence David M Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Jul 31/14 Jul 30/14 Jacobs M Christine Direct Ownership Restricted Stock Units A - Grant, award or other under Rule 16b-3(d) 785  
Sign up for a free account or login above to see all SEC filings within the past 6 months. During our beta offer, get free access to company PDF reports.
Sign up for a free account or login above to see the past 6 months of filings sorted by insider. During our beta offer, get free access to company PDF reports.
Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers
 
See Regulatory Filings on SEC
Key People
John Harvey Hammergren
Chairman of the Board, President, Chief Executive Officer
James A. Beer
Chief Financial Officer, Executive Vice President
Randall N. Spratt
Chief Information Officer, Chief Technology Officer, Executive Vice President
Lori A. Schechter
Executive Vice President, Chief Compliance Officer, General Counsel
Jorge L. Figueredo
Executive Vice President - Human Resources
Patrick J. Blake
Executive Vice President, Group President
Paul Coleman Julian
Executive Vice President, Group President
Brian S. Tyler
Executive Vice President - Corporate Strategy and Business Development
 
Company Contact
Address: MCKESSON PLAZA, ONE POST ST
SAN FRANCISCO CA 94104
Tel: 1-415-9838391
Website: www.mckesson.com
IR: www.mckesson.com/investors/stock-information/stock-information
Business Overview
McKesson Corporation delivers pharmaceuticals, medical supplies and healthcare information technologies. The Company operates in two segments: McKesson Distribution Solutions segment and McKesson Technology Solutions segment. The McKesson Distribution Solutions segment distributes drugs, medical-surgical supplies and equipment and health and beauty care products throughout North America. The McKesson Technology Solutions segment delivers enterprise clinical, patient care, financial, supply chain, strategic management software solutions, pharmacy automation for hospitals, as well as connectivity, outsourcing and other services, including remote hosting and managed services, to healthcare organizations. In February 2013, the Company completed acquisition of Pss World Medical Inc. In February 2014, McKesson Corporation announced that its ownership in Celesio AG exceeds 75% interest.
Financial Overview
For the three months ended 30 June 2014, McKesson Corporation revenues increased 37% to $44.06B. Net income before extraordinary items decreased 3% to $417M. Revenues reflect Distribution Solutions segment increase of 38% to $43.29B. Net income was offset by Operating Expenses increase of 67% to $2.11B (expense), Interest Expense increase of 71% to $101M (expense). Dividend per share increased from $0.20 to $0.24.
Employees: 42,800 as of Mar 31, 2014
Reporting Currency: U.S. Dollars
Enterprise value: $51,035M as of Jun 30, 2014
Annual revenue (TTM): $149,459M as of Jun 30, 2014
EBITDA (TTM): $3,713M as of Jun 30, 2014
Net annual income (TTM): $1,356M as of Jun 30, 2014
Free cash flow (TTM): $1,948M as of Jun 30, 2014
Net Debt Last Fiscal Year: $6,568M as of Jun 30, 2014
Shares outstanding: 232,000,000 as of Jun 30, 2014
Index Membership: S&P 500
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization
Competitors with Recent Insider Filings
Express Scripts Holding C (OQ:ESRX)
Cardinal Health (N:CAH)
AmerisourceBergen (N:ABC)